The clinical course of multiple sclerosis (MS) is highly variable among patients, thus creating
important challenges for the neurologist to appropriately treat and monitor patient progress …

Establishing the prognosis for multiple sclerosis (MS) early in the disease course is critically
important for patients who develop this disease. Potentially, this information could be used to …

The autoimmune disease multiple sclerosis (MS) is characterized by relapses in the majority
of patients. A definitive clinical diagnosis of relapse in MS can be complicated by the …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Personalized treatment is highly desirable in multiple sclerosis because it is an immensely
heterogeneous disease. This heterogeneity is seen in both the disease course and the …

The identification of progression in multiple sclerosis is typically retrospective. Given the
profound burden of progressive multiple sclerosis, and the recent development of effective …

The pursuit of personalized medicine requires the development of biomarkers to predict
disease course, monitor disease evolution, stratify patient subgroups by disease activity and …

A number of recent advances have been made in the clinical diagnosis and prognostication
of multiple sclerosis patients. Future research will enable the development of more accurate …

Multiple sclerosis (MS) is an autoimmune disease of unknown cause, in which chronic
inflammation drives multifocal demyelination of axons in both white and gray matter in the …

Multiple sclerosis (MS) is a chronic progressive disease and many patients transition from
an initial relapsing–remitting course to a secondary progressive pattern. Accurate …